{"summary":"I am a passionate builder and leader of high-performing cross-functional teams across a molecule's lifecycle. I have experience in all phases of drug development, particularly in driving NMEs from bench to bedside and through proof-of-concept. I am seasoned in both solid tumor and hematologic malignancies and have worked on small molecule inhibitors, cell therapy, and targeted therapies.\n\nI am currently using these skills to lead 3 early-stage programs as the program team leader and global development lead, including our novel next-generation ADCs in hematologic malignancies. I believe in facing obstacles & overcoming challenges with an open-mind, open hands, and an open heart.","lastName":"Chen","objectUrn":"urn:li:member:121271030","geoRegion":"South San Francisco, California, United States","fullName":"Tara L. Chen","firstName":"Tara L.","currentPositions":[{"companyName":"Seagen","description":"- Leading cross-functional Project Teams focused on the development of novel oncology therapeutics \n- Leading the Clinical Development strategy and overseeing & guiding multiple project teams on execution of strategy and early phase studies","title":"Medical Director","companyUrnResolutionResult":{"employeeCountRange":"1001-5000","headquarters":{"geographicArea":"Washington","country":"United States","city":"Bothell","postalCode":"98021","line1":"21823 30th Dr SE"},"revenue":{"amount":"4.8225E+8","currencyCode":"USD"},"flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/seagen\/","formattedRevenue":{"unit":"MILLION","amount":482.3,"currencyCode":"USD"},"industry":"Biotechnology Research"},"companyUrn":"urn:li:fs_salesCompany:21407","tenureAtCompany":{"numYears":2,"numMonths":11},"startedOn":{"month":10,"year":2022}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1668047204395?e=1723075200&v=beta&t=dbPDEIK7bdyGrTgU8sDp6nD4xN0zs7bj_xKYRjqNvnk","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1668047204395?e=1723075200&v=beta&t=xgnxwKGZTszbOyhC_Ft6lqfMxDDPGc2QeZyi8dAy0bU","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1668047204395?e=1723075200&v=beta&t=wnmDntENa9Mbbuu39p9s58SAEVyr0PjWXw7FksGiiXc","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1668047204395?e=1723075200&v=beta&t=qI7fWIWkBNNzrMn3vuv8uKbkRV7V2-0ckKgwY9zYGIg","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C5603AQG65k1hOc-RHw\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Biotechnology Research","educations":[{"endedOn":{"year":2005},"degree":"PharmD","eduId":71791306,"schoolUrn":"urn:li:fs_salesSchool:4262","school":"urn:li:fs_salesSchool:4262","fieldsOfStudy":["Pharmacy"],"schoolName":"Rutgers, The State University of New Jersey-New Brunswick","startedOn":{"year":1999}}],"skills":[{"numOfEndorsement":0,"name":"Medical Data Interpretation"},{"numOfEndorsement":0,"name":"Trial Management"},{"numOfEndorsement":0,"name":"Direct Patient Care"},{"numOfEndorsement":0,"name":"Team Leadership"},{"numOfEndorsement":0,"name":"Cross-functional Team Leadership"},{"numOfEndorsement":42,"name":"Clinical Research"},{"numOfEndorsement":23,"name":"Hematology"},{"numOfEndorsement":11,"name":"Clinical Trials"},{"numOfEndorsement":18,"name":"Inpatient"},{"numOfEndorsement":17,"name":"Oncology"},{"numOfEndorsement":15,"name":"Pharmacy"},{"numOfEndorsement":9,"name":"Patient Safety"},{"numOfEndorsement":9,"name":"Cancer"},{"numOfEndorsement":8,"name":"Medical Writing"},{"numOfEndorsement":7,"name":"Medicine"},{"numOfEndorsement":7,"name":"Critical Care"},{"numOfEndorsement":6,"name":"Healthcare Management"},{"numOfEndorsement":5,"name":"Medical Education"},{"numOfEndorsement":5,"name":"Informatics"},{"numOfEndorsement":5,"name":"Clinical Development"},{"numOfEndorsement":4,"name":"Pharmaceutical Industry"},{"numOfEndorsement":4,"name":"Cell"},{"numOfEndorsement":4,"name":"Medication Therapy Management"},{"numOfEndorsement":3,"name":"Public Health"},{"numOfEndorsement":3,"name":"Healthcare Information Technology"},{"numOfEndorsement":3,"name":"Internal Medicine"},{"numOfEndorsement":2,"name":"Lifesciences"},{"numOfEndorsement":2,"name":"Epidemiology"},{"numOfEndorsement":2,"name":"Healthcare Information Technology (HIT)"},{"numOfEndorsement":2,"name":"Inpatient Care"},{"numOfEndorsement":2,"name":"Life Sciences"},{"numOfEndorsement":1,"name":"Cell Biology"},{"numOfEndorsement":0,"name":"Drug Development"},{"numOfEndorsement":21,"name":"Infectious Diseases"},{"numOfEndorsement":6,"name":"Pharmacy Practice"},{"numOfEndorsement":4,"name":"Critical Care Medicine"},{"numOfEndorsement":2,"name":"Clinical Pharmacology"},{"numOfEndorsement":0,"name":"Protocol Development"},{"numOfEndorsement":1,"name":"Protocol Writing"},{"numOfEndorsement":0,"name":"Protocol"},{"numOfEndorsement":9,"name":"Pharmacists"},{"numOfEndorsement":1,"name":"Teaching\/mentoring"}],"pronoun":"She\/Her","numOfConnections":1254,"patents":[],"headline":"Global Development Lead \/ Program Team Lead, Early Stage Development at Seagen","courses":[],"certifications":[{"endedOn":{"month":12,"year":2022},"authority":"Board of Pharmacy Specialties (BPS)","name":"Board Certification in Oncology Pharmacy (BCOP)","startedOn":{"month":10,"year":2008}}],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/tara-l-chen-pharmd-bcop","organizations":[],"location":"South San Francisco, California, United States","publications":[{"name":"Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML): A Phase 1\/2 Study","publishedOn":{"month":2,"year":2013},"publisher":"Leukemia & Lymphoma","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]},{"name":"Idarubicin, cytarabine and pravastatin as induction  therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.","publishedOn":{"month":2,"year":2015},"publisher":"Am J Hematol.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]},{"name":"A phase 1 study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in   patients with relapsed lymphoma.","publishedOn":{"month":1,"year":2013},"publisher":"Br J Haematol.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]},{"name":"Addressing treatment challenges in the nontransplant setting for myeloma. ","publishedOn":{"month":2,"year":2012},"publisher":"Value-Based Care in Myeloma.","url":"http:\/\/www.valuebasedmyeloma.com\/articles\/1276-vbm-1276","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]},{"name":"Changing the treatment paradigm in myelodysplastic syndromes. ","publishedOn":{"month":10,"day":1,"year":2008},"publisher":"Cancer Control.","url":"http:\/\/europepmc.org\/abstract\/med\/18813206","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]},{"name":"Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed\/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1\/2 Study. ","publishedOn":{"year":2017},"publisher":"Leukemia.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]},{"name":"Phase 1\/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms","publishedOn":{"month":4,"year":2018},"publisher":"Leukemia","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAc6cvYBqvu0IVfl4Bbq3ufRUZ1yaBKgeJc,NAME_SEARCH,HJDL)"}]}],"positions":null,"posts":[{"createdAt":1715641980000,"insightId":"f2016d16-fb97-4d5d-997c-8f458cdbb0f2","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":14},{"type":"PRAISE","count":4}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7195924129475121152","threadUrn":"urn:li:activity:7195924129475121152","reactionsCount":18,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7195924128808198144","message":{"attributes":[{"start":71,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:360698484"}}}],"text":"Incredibly proud and thrilled for my good friend and former colleague, Bart Scott, in recognition of his dedication and contributions to the field of MDS research and care. We continue to make inroads to the treatment of MDS, particularly for those patients with higher-risk disease -- but still have a ways to go. "},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQGMetsApTqEsQ\/image-shrink_1280\/0\/1715538002906?e=1717977600&v=beta&t=2a6Nken0684r6BLzLR1gpJCCWCeOn7v9Vb_rhQd56xU","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQGMetsApTqEsQ\/image-shrink_1280\/0\/1715538002906?e=1717977600&v=beta&t=2a6Nken0684r6BLzLR1gpJCCWCeOn7v9Vb_rhQd56xU"}]},"description":"Nearly 25 years after arriving at Fred Hutch Cancer Center for his hematology-oncology fellowship, Bart Scott, MD, has been named the Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair, established to support myelodysplastic syndrome research.","resolvedUrl":"https:\/\/bit.ly\/4bbgwp7","title":"Dr. Bart Scott named Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7195487907397210112","message":{"attributes":[{"start":445,"length":22,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/bit.ly\/4bbgwp7"}}}],"text":"Nearly 25 years after arriving at Fred Hutch Cancer Center for his hematology-oncology fellowship, Bart Scott, MD, has been named the Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair, established to support myelodysplastic syndrome research.\n\n\u201cIt\u2019s a great honor. I think of this as not simply recognition of the work I\u2019ve done up to now but also of the work that we have yet to do to continue improving MDS care,\u201d said Scott.\n\nRead more: https:\/\/bit.ly\/4bbgwp7"},"entityUrn":"urn:li:share:7195487907397210112"},"entityUrn":"urn:li:share:7195924128808198144"}}},{"createdAt":1709915340000,"insightId":"b8a4dda5-d4e6-4bcd-b180-f1b497d702ff","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"PRAISE","count":3},{"type":"APPRECIATION","count":1},{"type":"ENTERTAINMENT","count":1},{"type":"LIKE","count":15},{"type":"EMPATHY","count":5}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7171904769702117378","threadUrn":"urn:li:ugcPost:7171904769702117378","reactionsCount":25,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171904769702117378","message":{"attributes":[{"start":270,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womensleadership"}}},{"start":288,"length":21,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womenempoweringwomen"}}},{"start":310,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:iwd2024"}}},{"start":319,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:inspireinclusion"}}}],"text":"Celebrating the amazing, resilient, fierce, badass women I know who show up as leaders in all facets of life. May we continue to empower, support, and include women today and every day.\n\nThe article below really resonated with me -- and the cartoon gave me a giggle :)\n\n#womensleadership #womenempoweringwomen #IWD2024 #inspireinclusion  "},"rootActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:linkedInArticle:7170075427741380608"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171896437197131776","message":{"attributes":[{"start":209,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womeninleadership"}}},{"start":228,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womenshistorymonth"}}},{"start":248,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:iwd2024"}}},{"start":257,"length":27,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:internationalwomensday2024"}}},{"start":285,"length":22,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:leadershipdevelopment"}}}],"text":"For Women's History Month and International Women's Day, let's talk about the invisible work we don't discuss: emotional labor. Check out my post, which pulls from several of my newsletter articles on this. \n\n#womeninleadership #womenshistorymonth #iwd2024 #internationalwomensday2024 #leadershipdevelopment "},"entityUrn":"urn:li:ugcPost:7171896437197131776"},"entityUrn":"urn:li:ugcPost:7171904769702117378"}}},{"createdAt":1713449340000,"insightId":"69d29dcf-6ce5-47cf-8c91-66ed17e1e8c7","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7186045552139100160,7186727467657650177)","threadUrn":"urn:li:activity:7186045552139100160","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:325911232"}}}],"text":"Jeremy Sauer you are the coolest. I am honored to know you"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7186045552139100160"}}},{"createdAt":1709664600000,"insightId":"c4209cc7-21dd-4b09-874a-e6764b62b219","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7169443488432869376,7170853154064904192)","threadUrn":"urn:li:activity:7169443488432869376","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"thanks for your partnership and collaboration, Priya! it is a pleasure to work with you on our early pipeline!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7169443488432869376"}}},{"createdAt":1709664540000,"insightId":"009d2b46-db24-416c-8b60-a894df40c8f0","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"INTEREST","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7169443488432869376,7170852982916407296)","threadUrn":"urn:li:activity:7169443488432869376","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"thank you, Ena -- teamwork! all your contributions will be carried forward with these molecules. thank you for all that you've done!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7169443488432869376"}}},{"createdAt":1709615160000,"insightId":"46e24fbb-65c4-49d8-9df3-7d02ca2fe504","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1},{"type":"EMPATHY","count":4}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7169021254606290945,7170645927332962305)","threadUrn":"urn:li:activity:7169021254606290945","reactionsCount":5,"commentsCount":1,"canComment":true},"commentary":{"attributes":[{"start":53,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:21752757"}}},{"start":96,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:278272780"}}},{"start":114,"length":29,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:10259567"}}},{"start":145,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:335120908"}}},{"start":160,"length":25,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:320512560"}}},{"start":190,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:764772429"}}}],"text":"An inspiring and dynamic meeting with my compatriots Jenny Hahn, Sarah Thomas, Lilit Petrosyan, Jennifer LeSourd, AnnChristine (Kicki) Thastrom, Nansi Kabonge, Madeena (Faria) Siddiqui, and Rebeca Hayes."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7169021254606290945"}}}]}